(Q37998761)

26 August 2017

title

Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases (English)

1 reference

26 August 2017

0 references

1 reference

Bob W van Oosten

4

0 references

Marinus Blankenstein

object named as

Marinus A Blankenstein

5

0 references

Charlotte Teunissen

6

object named as

Charlotte Teunissen

1 reference

26 August 2017

Arjan Malekzadeh

1

1 reference

26 August 2017

Vincent de Groot

2

1 reference

26 August 2017

Heleen Beckerman

3

1 reference

26 August 2017

publication date

24 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

56

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

508-513

1 reference

26 August 2017

cites work

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Risks in new drug development: approval success rates for investigational drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Anti-cytokine therapy for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Mechanisms of disease: Inflammation and the origins of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Cell-surface and cytokine biomarkers in autoimmune and inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Tumor necrosis factor, other cytokines and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Immunological markers in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Inflammation and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Th1/Th2 cytokine patterns and clinical profiles during and after pregnancy in women with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Fatigue in neurological disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Transcriptional analysis of targets in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Inflammation and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

The role of inflammation in CNS injury and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Novel anti-inflammatory therapy for Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Enzyme-labeled antibodies: preparation and application for the localization of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Enzyme-labeled antibodies for the light and electron microscopic localization of tissue antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

HIV diagnostic tests: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Enzyme-immunoassay: a powerful analytical tool

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Comparison of multiplex immunoassay platforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

ELISA and multiplex technologies for cytokine measurement in inflammation and aging research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Antibody-based protein multiplex platforms: technical and operational challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Multiplexed protein measurement: technologies and applications of protein and antibody arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Multisite comparison of high-sensitivity multiplex cytokine assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Validity of multiplex-based assays for cytokine measurements in serum and plasma from "non-diseased" subjects: comparison with ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Staging of brain pathology related to sporadic Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Identifying and validating biomarkers for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Parkinson's disease: clinical features and diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Biomarkers for neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Immunological patterns identifying disease course and evolution in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Cytokines in multiple sclerosis: from bench to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Review: cytokines and the pathogenesis of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

The cytokine storm in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

The genetic aspects of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

What role for genetics in the prediction of multiple sclerosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Circulating cytokines as biomarkers of alcohol abuse and alcoholism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Mechanisms underlying inflammation in neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Elevated circulating tumor necrosis factor levels in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Serum inflammatory biomarkers in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.017

inferred from DOI database lookup

7 January 2021

based on heuristic

Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies

1 reference

COCI

https://opencitations.net/index/api/v1/citations/10.1155/2011/246412

10.1016/J.YMETH.2012.03.017

30 December 2023

Identifiers

DOI

1 reference

26 August 2017

1 reference